Error loading player: No playable sources found
64253
Parallel Session 10: Platform Development Approaches for AAV Gene Therapy Products
Date
June 29, 2023
This product is not available for individual purchase, but it is available as part of the following products:
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…
With the recent approval of several Adeno-Associated Virus (AAV)-based gene therapies, the application of AAV gene therapy approaches to the treatment of human disease is expanding. AAV is emerging as the vector of choice for gene therapy based on a developing understanding of numerous features of its utility, including, but not limited to its’ safety, versatility, durability, and manufacturing approaches.
As this knowledge base expands, a given AAV quality target product profile (i.e., specific AAV serotype for targeting a specific organ or cell types) may lend itself to being the basis for a platform approach to product development for targeting specific monogenic diseases impacting similar target organs or cell types.
The advantages to this approach can be to leverage prior knowledge from preclinical studies and manufacturing process development, including an understanding of product critical quality attributes, critical process parameters for process steps, including those assessed for virus clearance, analytical methods and other elements of the control strategy, to create synergies for other products in development. This synergistic platform approach to AAV development is essential to help reduce costs, streamline development, and ultimately deliver these products to the patients who need them more efficiently.
This session will highlight different approaches taken by industry, CMOs and other organizations and illustrate their experience, including the benefits achieved with the application of platform approaches to AAV product development.
Session Speakers:
Establishing Analytical Tools for an AAV Platform
Melissa Clague, Eli Lilly and Company
Assembling Complex Lego Blocks - Building AAV Manufacturing Platforms
John Kerwin, National Resilience, Inc.
NIH Programs Supporting the Development of AAV as a Therapeutic Platform
PJ Brooks, NCATS, NIH
Additional Panelists:
Christiane Niederlaender, Parexel International
As this knowledge base expands, a given AAV quality target product profile (i.e., specific AAV serotype for targeting a specific organ or cell types) may lend itself to being the basis for a platform approach to product development for targeting specific monogenic diseases impacting similar target organs or cell types.
The advantages to this approach can be to leverage prior knowledge from preclinical studies and manufacturing process development, including an understanding of product critical quality attributes, critical process parameters for process steps, including those assessed for virus clearance, analytical methods and other elements of the control strategy, to create synergies for other products in development. This synergistic platform approach to AAV development is essential to help reduce costs, streamline development, and ultimately deliver these products to the patients who need them more efficiently.
This session will highlight different approaches taken by industry, CMOs and other organizations and illustrate their experience, including the benefits achieved with the application of platform approaches to AAV product development.
Session Speakers:
Establishing Analytical Tools for an AAV Platform
Melissa Clague, Eli Lilly and Company
Assembling Complex Lego Blocks - Building AAV Manufacturing Platforms
John Kerwin, National Resilience, Inc.
NIH Programs Supporting the Development of AAV as a Therapeutic Platform
PJ Brooks, NCATS, NIH
Additional Panelists:
Christiane Niederlaender, Parexel International
General
Tracks
Related Products
Parallel Session 1: CMC Challenges with Ultra Rare Diseases
Bringing treatment to those afflicted with an ultra-rare disease is complex. These products are encumbered with challenges ranging from high development costs with a limited ROI, to issues with executing and interpreting clinical trials with unusually small patient populations…
Parallel Session 7: Unique Challenges of Stability Testing for Cell and Gene Therapy Products
Cell and Gene Therapy programs are progressing from early academic settings to commercial manufacturing at increasingly faster pace and in greater numbers. These therapies are complex, difficult to manufacture in large quantities, and involve many bespoke technologies to make, test and release…
Keynote Presentation
Gene Therapy Drug Development for Ultra-Rare Disease: Challenges & Opportunities
